Rein Therapeutics Inc.
RNTX
$0.83
-$0.04-4.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.20% | 81.74% | -472.78% | 18.19% | -24.01% |
| Total Depreciation and Amortization | -- | -- | -- | -100.00% | -- |
| Total Amortization of Deferred Charges | -27.45% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 273.72% | -99.46% | 1,470.49% | 621.48% | -3.03% |
| Change in Net Operating Assets | -301.83% | 728.85% | -239.78% | 26.53% | 115.67% |
| Cash from Operations | -152.34% | -6.34% | 9.24% | 44.72% | -3.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | 326.32% | -200.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14,925.42% | -75.67% | -- | -100.00% | 68.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 927.40% | 93.51% | 26.58% | -59.68% | 538.48% |
| Foreign Exchange rate Adjustments | -- | -- | 30.77% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 233.09% | 247.66% | 50.24% | 1.88% | 68.62% |